All sponsors

Miltenyi Biomedicine GmbH

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-30
RECRUITING8
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO33%

Delay Index: of 6 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +5.6 months). See all sponsors →

Open Miltenyi Biomedicine GmbH on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
DALY 2-EU
NCT04844866
P2RecruitingDiffuse Large B-cell Lymphoma2132025-01-15
CASTLE
NCT06347718
P1/2RecruitingSystemic Lupus Erythematosus; Systemic Sclerosis242026-05-31
zamtocabtagene autoleucel (MB-CART2019.1)
NCT04792489
P2RecruitingRefractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma3152026-12-31 (+56 mo)
DALY II Japan
NCT07288879
P2RecruitingDLBCL - Diffuse Large B Cell Lymphoma; CAR T Cell Therapy312027-01-31
MB-CART19.1
NCT06189157
P1/2RecruitingSLE - Systemic Lupus Erythematosus292027-09-30 (+31 mo)
MB-dNPM1-TCR.1
NCT06424340
P1/2RecruitingLeukemia, Myeloid, Acute292028-06
FRONTIER
NCT07569965
P2Not yet recruitingMantle Cell Lymphoma (MCL)522029-09
DALY PED
NCT06508931
P2RecruitingB-Cell Neoplasm312029-12-31 (+3 mo)
MB-CART2019.1
NCT07178431
P1/2RecruitingMultiple Sclerosis; CAR T Cell Therapy262030-08-16 (+6 mo)